Table 1 Basic information and clinical benefit evidence for four groups of nine targeted anticancer medicines
Group | Generic name | Marketing authorization holder | Therapeutic classa | ATC code | CSCO guidelineb recommendation | NCCN guidelinec recommendation | Clinical benefit comparison | Category of evidence |
|---|---|---|---|---|---|---|---|---|
1 | Sintilimab | Innovent | Hodgkin lymphoma | / | Recommended | Not mentioned | Sintilimab: OR 80.4%; CR 34% Camrelizumab: OR 76.0%; CR 28.0% | |
Camrelizumab (reference) | HengRui | / | Not mentioned | Not mentioned | ||||
2 | Alectinib | Roche | NSCLC | L01XE36 | First-line therapy Preferred | First-line therapy Preferred | Alectinib vs crizotinib PFS (months): NE vs 10.2, p < 0.001 | Randomized controlled trial [18] |
Crizotinib (reference) | Pfizer | L01XE16 | First-line therapy Recommended | First-line therapy Other Recommended | ||||
3 | Pyrotinib | HengRui | Breast cancer | / | Second-line therapy Recommended | Not Mentioned | Pyrotinib vs lapatinib ORR: 78.5% vs 57.1, p = 0.01 PFS (months): 18.1 vs 7.0, p < 0.001 | Randomized controlled trial [19] |
Lapatinib (reference) | GlaxoSmithKline | L01XE07 | Second-line therapy Preferred | Other Recommended | ||||
4 | Erlotinib | Roche | NSCLC | L01XE03 | First-line therapy Recommended | First-line therapy Other Recommended | No significant difference in PFS and overall survival | Network meta-analysis [20] |
Icotinib (reference) | Betta | / | First-line therapy Recommended | Not Mentioned | ||||
Gefitinib (reference) | AstraZeneca | L01XE02 | First-line therapy Recommended | First-line therapy Other Recommended |